VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISHL HL Update 2021 | Novel approaches in HL

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, explores the next steps in the treatment and management of Hodgkin lymphoma, including the development of second-generation anti-PD-1 antibodies, CD30-targeting CAR T-cell therapies, as well as combination strategies investigated in relapsed/refractory HL patients. Dr Bröckelmann also touches on areas of unmet needs in HL, including the treatment of older HL patients, the importance of identifying response biomarkers as well as rational combination strategies. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter